TuHURA Biosciences Files 8-K
Ticker: HURA · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1498382
Sentiment: neutral
Topics: 8-K, corporate-filing, pharmaceutical
TL;DR
TuHURA Bio filed an 8-K on Nov 18, 2025. Important for investors tracking company updates.
AI Summary
TuHURA Biosciences, Inc. filed an 8-K on November 18, 2025, reporting other events and financial statements. The company, formerly known as Kintara Therapeutics, Inc., is incorporated in Nevada and headquartered in Tampa, Florida.
Why It Matters
This filing indicates TuHURA Biosciences is providing updates on its corporate activities and financial status, which is important for investors to monitor the company's progress.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events but doesn't inherently introduce new risks.
Key Numbers
- 001-37823 — SEC File Number (Identifies the company's filing with the SEC.)
- 99-0360497 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- Kintara Therapeutics, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Tampa, Florida (location) — Business address
- November 18, 2025 (date) — Date of report
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond stating that this item is included in the filing.
What are the primary business activities of TuHURA Biosciences, Inc.?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]', indicating its business is in the pharmaceutical sector.
When did TuHURA Biosciences, Inc. change its name from Kintara Therapeutics, Inc.?
The filing states the date of the name change from Kintara Therapeutics, Inc. was August 20, 2020.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Where is TuHURA Biosciences, Inc. physically located?
The company's business address is 10500 University Center Dr., Suite 110, Tampa, Florida 33612.
Filing Stats: 920 words · 4 min read · ~3 pages · Grade level 13.4 · Accepted 2025-11-18 17:03:56
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
Filing Documents
- d851083d8k.htm (8-K) — 30KB
- d851083dex991.htm (EX-99.1) — 258KB
- 0001193125-25-286419.txt ( ) — 446KB
- hura-20251118.xsd (EX-101.SCH) — 3KB
- hura-20251118_lab.xml (EX-101.LAB) — 18KB
- hura-20251118_pre.xml (EX-101.PRE) — 11KB
- d851083d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are not guarantees of future performance and that TuHURA's actual results may differ materially from those set forth in the forward-looking statements. All of these forward-looking statements are subject to risks and uncertainties that may change at any time. Factors that could cause TuHURA's actual expectations to differ materially from these forward-looking statements and include the factors under the heading "Risk Factors" set forth in TuHURA's Annual Report on Form 10-K, as supplemented by TuHURA's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Such filings are available on our website or at www.sec.gov. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof. TuHURA undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: November 18, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer